← Leaderboards
John E. Mendelson
University Of California San Francisco
$11,971,442
Attributed
$11,971,442
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.3M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$17,757,263 · 12
By mechanism
P50$8,889,913 · 3
R01$5,999,478 · 4
R44$2,096,748 · 1
M01$771,124 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Reese T. Jones$7,250,168
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchMethamphetaminePharmacokineticsPsychopharmacologyPharmaceutical PreparationsDrug InteractionsCravingDrug Screening /EvaluationLaboratoriesAdrenergic AgentsStereoisomerResearch StudyDrug Abuse ChemotherapyDoseEchocardiographyUrinaryUrineCocaineArgipressinAcuteNeuropharmacologyAdrenergicHuman Therapy Evaluation
Grant awards (50)
A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder$943,481
R44 · FY2024 · AA · contact PI
A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder$886,202
R44 · FY2023 · AA · contact PI
A Telehealth Intervention to Increase Screening and Treatment for Alcohol Use Disorder$267,065
R44 · FY2022 · AA · contact PI
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines$440,122
R01 · FY2010 · DA · contact PI
A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP$337,500
R01 · FY2010 · DA · contact PI
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines$432,550
R01 · FY2009 · DA · contact PI
Methamphetamine Pharmacotherapy Development Center$226,812
P50 · FY2009 · DA · contact PI
Evaluation of Adrenergic Pharmacotherapies for d-MA Dependence$93,598
P50 · FY2009 · DA · contact PI
Core--Clinical pharmacology, med. selection, method devel., analytic chemisistry$50,917
P50 · FY2009 · DA · contact PI
Methamphetamine Pharmacotherapy Development Center$1,114,987
P50 · FY2008 · DA · contact PI
MDMA Dependence and Discontinuation Syndrome$451,866
R01 · FY2008 · DA · contact PI
Evaluation of Adrenergic Pharmacotherapies for d-MA Dependence$444,908
P50 · FY2008 · DA · contact PI
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines$415,799
R01 · FY2008 · DA · contact PI
Core--Clinical pharmacology, med. selection, method devel., analytic chemisistry$272,479
P50 · FY2008 · DA · contact PI
MDMA Dependence and Discontinuation Syndrome$83,750
R01 · FY2008 · DA · contact PI
MDMA Dependence and Discontinuation Syndrome$449,003
R01 · FY2007 · DA · contact PI
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines$419,673
R01 · FY2007 · DA · contact PI
Methamphetamine Pharmacotherapy Development Center$2,055,171
P50 · FY2006 · DA · contact PI
Adrenergic Pharmacotherapies for d-MA Depependence$475,921
P50 · FY2006 · DA · contact PI
MDMA Dependence and Discontinuation Syndrome$453,827
R01 · FY2006 · DA · contact PI
Core--Clinical pharm., med. selection, method devel.$275,476
P50 · FY2006 · DA · contact PI
Methamphetamine Pharmacotherapy Development Center$1,203,803
P50 · FY2005 · DA
Adrenergic Pharmacotherapies for d-MA Depependence$465,741
P50 · FY2005 · DA
MDMA Dependence and Discontinuation Syndrome$461,918
R01 · FY2005 · DA
Core--Clinical pharm., med. selection, method devel.$269,918
P50 · FY2005 · DA
INTERACTIONS BETWEEN SINGLE DOSE OF ORAL RESERPINE &INTRAVENOUS METHAMPHETAMINE$190,334
M01 · FY2005 · RR
INTERACTION BETWEEN SEROTONIN REUPTAKE BLOCKER PAROXETINE &METHAMPHETAME$60,794
M01 · FY2005 · RR
Methamphetamine Pharmacotherapy Development Center$1,185,048
P50 · FY2004 · DA
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines$493,572
R01 · FY2004 · DA
Adrenergic Pharmacotherapies for d-MA Depependence$491,567
P50 · FY2004 · DA
Core--Clinical pharm., med. selection, method devel.$263,567
P50 · FY2004 · DA
Interactions Between Single Dose of Oral Reserpine &Intravenous Methamphetamine$61,453
M01 · FY2004 · RR
Clinical Pharmacology of l-Methamphetamine$31,944
M01 · FY2004 · RR
Interaction Between Serotonin Reuptake Blocker Paroxetine &Methamphetame$14,603
M01 · FY2004 · RR
CLINICAL PHARMACOLOGY OF METHAMPHETAMINE STEREOISOMERS$407,433
R01 · FY2003 · DA
CLINICAL PHARMACOLOGY OF METHAMPHETAMINE STEREOISOMERS$395,566
R01 · FY2002 · DA
EFFECTS OF CONTINUOUS COCAINE EXPOSURE ON TOLERANCE &CRAVING$68,666
M01 · FY2002 · RR
Clinical pharmacology of methamphetamine stereoisomers$68,666
M01 · FY2002 · RR
Pharmacokinetic interactions:selegiline and cocaine$68,666
M01 · FY2002 · RR
CLINICAL PHARMACOLOGY OF METHAMPHETAMINE STEREOISOMERS$384,044
R01 · FY2001 · DA
Pharmacokinetic interactions:selegiline and cocaine$68,666
M01 · FY2001 · RR
EFFECTS OF CONTINUOUS COCAINE EXPOSURE ON TOLERANCE &CRAVING$68,666
M01 · FY2001 · RR
Clinical pharmacology of methamphetamine stereoisomers$68,666
M01 · FY2001 · RR
Clinical pharmacology of methamphetamine stereoisomers$0
M01 · FY2001 · RR
Pharmacokinetic interactions:selegiline and cocaine$0
M01 · FY2001 · RR
EFFECTS OF CONTINUOUS COCAINE EXPOSURE ON TOLERANCE &CRAVING$0
M01 · FY2001 · RR
CLINICAL PHARMACOLOGY OF METHAMPHETAMINE STEREOISOMERS$372,855
R01 · FY2000 · DA
Pharmacokinetic interactions:selegiline and cocaine$0
M01 · FY2000 · RR
Clinical pharmacology of methamphetamine stereoisomers$0
M01 · FY2000 · RR
EFFECTS OF CONTINUOUS COCAINE EXPOSURE ON TOLERANCE &CRAVING$0
M01 · FY2000 · RR